LoriJWirthMD

Oncology • Boston, MA

Assistant Professor of Medicine, Massachusetts General Hospital

Join to view full profile

Dr. Wirth is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Wirth's full profile

Already have an account?

Office
44 Binney St SW 430
Dfci Head and Neck Oncology
Boston, MA 02115
Phone+1 617-632-3090

Fax+1 617-692-4448

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2000 - 2003
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1997 - 2000
Columbia University Vagelos College of Physicians and SurgeonsClass of 1997

Certifications & Licensure

ME State Medical License 2021 - 2026
RI State Medical License 2021 - 2026
MA State Medical License 2000 - 2025
NH State Medical License 2013 - 2025
NY State Medical License 1998 - 2000
American Board of Internal Medicine Medical Oncology

Clinical Trials

Celecoxib in Preventing Cancer in Patients With Oral Leukoplakia and/or Head and Neck Dysplasia Start of enrollment: 2002 Jun 01
Completed
Phase 2
Capecitabine For Nasopharyngeal Cancer Start of enrollment: 2004 Jun 01
Completed
Phase 2
Bowman-Birk Inhibitor Concentrate in Preventing Cancer in Patients With Oral Leukoplakia Start of enrollment: 1999 Jan 01
Completed
Phase 2
Panitumumab Chemoradiotherapy Chemotherapy for Squamous Cancer of the Head and Neck Start of enrollment: 2006 Apr 01
Completed
Phase 1
Safety and Efficacy of VB-111 in Subjects With Advanced Differentiated Thyroid Cancer Start of enrollment: 2010 Dec 01
Completed
Phase 2
Phase I Study of CUDC-101 With Cisplatin and Radiation in Subjects With Head & Neck Cancer Start of enrollment: 2011 Nov 01
Completed
Phase 1
A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Start of enrollment: 2012 Nov 12
Terminated
Phase 1, Phase 2
Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer Start of enrollment: 2012 Nov 07
Active, not recruiting
Phase 2
Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer Start of enrollment: 2013 May 08
Completed
Phase 2
2 Phase Use Of Educational Materials In Head And Neck Cancer Center Start of enrollment: 2014 Aug 12
Completed
Not Applicable
Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC) Start of enrollment: 2018 Feb 07
Completed
Phase 2
Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma Start of enrollment: 2017 Apr 25
Completed
Phase 2
Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC Start of enrollment: 2023 Mar 01
Recruiting
Phase 2
Roles: Contact, Principal Investigator
A Study of EP0031 in Patients With Advanced RET-altered Malignancies Start of enrollment: 2022 Sep 30
Recruiting
Phase 1, Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Fundamentals and recent advances in the evaluation and management of medullary thyroid carcinoma.
Benjamin J Gigliotti, Jennifer A Brooks, Lori J Wirth
Molecular and Cellular Endocrinology. 2024-10-01
1 citations
Durability of Response With Selpercatinib in Patients With-Activated Thyroid Cancer: Long-Term Safety and Efficacy From LIBRETTO-001.
Lori J Wirth, Marcia S Brose, Vivek Subbiah, Francis Worden, Ben Solomon
Journal of Clinical Oncology. 2024-09-20
Immune Cell Densities Predict Response to Immune Checkpoint-Blockade in Head and Neck Cancer.
Daniel A Ruiz-Torres, Michael E Bryan, Shun Hirayama, Ross D Merkin, Evelyn Luciani
Medrxiv. 2024-09-12

Journal Articles

Efficacy of Selpercatinib in RET-Altered Thyroid Cancers
Lori J Wirth, Jochen Lorch, Francis Worden, Marcia Brose, Taofeek K Owonikoko, Mark E Burkard, Todd M Bauer, Viola W Zhu, Nehal Lakhani, Victor Moreno, Manisha H Shah, New England Journal of Medicine
Still Perfecting Radioiodine in Thyroid Cancer, After All These Years
Lori Wirth, MD, The Journal of Clinical Endocrinology and Metabolism
Selective RET Kinase Inhibition for Patients with RET-Altered Cancers
L J Wirth, N L Busaidy, M E Cabanillas, Annals of Oncology

Lectures

Influence of tumor size and Eastern Cooperative Oncology Group performance status (ECOG PS) at baseline on patient (pt) outcomes in lenvatinib-treated radioiodine-refr...
2019 ASCO Annual Meeting - 6/1/2019
Genomic landscape of FNAs positive for medullary thyroid cancer (MTC) and potential impact on systemic therapy.
2019 ASCO Annual Meeting - 6/1/2019
Phase I/II study of spartalizumab (PDR001), an anti-PD1 mAb, in patients with anaplastic thyroid cancer.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Authored Content

Efficacy of Selpercatinib in RET-Altered Thyroid CancersAugust 2020
Efficacy of Selpercatinib in RET-Altered Thyroid CancersAugust 2020
Efficacy of Selpercatinib in RET-Altered Thyroid CancersAugust 2020

Press Mentions

Dr. Wirth on Questions About the Use of Selpercatinib in Advanced RET-Fusion+ Thyroid CancerJuly 11th, 2024
How Boston Is Beating CancerJanuary 24th, 2023
The Beginning of the American Thyroid Association Centennial YearJanuary 1st, 2023
Join now to see all